8-KLeadership Changes

BIOGEN INC. 8-K Report, Executive Changes (Dec 14, 2011)

Filed December 14, 2011For Securities:BIIB

Summary

Biogen Idec Inc. (BIIB) has filed an 8-K report on December 14, 2011, detailing amendments to its Supplemental Savings Plan and Voluntary Board of Directors Savings Plan, effective January 1, 2012. These amendments allow for voluntary deferrals of equity-based awards granted under the company's 2008 Omnibus Equity Plan and 2006 Non-Employee Directors Equity Plan, respectively, and any future successor plans. This change is primarily an administrative adjustment to enhance the flexibility of executive and director compensation by enabling them to defer the receipt of equity awards. While not a significant operational or financial event, it signals an ongoing commitment to providing competitive and flexible compensation structures for key personnel. Investors should view this as a standard practice for companies managing executive and director compensation, allowing for tax planning and long-term alignment of interests.

Key Highlights

  • 1Amendments to Supplemental Savings Plan and Voluntary Board of Directors Savings Plan are effective January 1, 2012.
  • 2Plan amendments permit voluntary deferrals of equity-based awards.
  • 3Deferrals can be made from awards granted under the 2008 Omnibus Equity Plan.
  • 4Deferrals can be made from awards granted under the 2006 Non-Employee Directors Equity Plan.
  • 5The amendments apply to these plans and any successor equity plans.
  • 6This change provides increased flexibility in executive and director compensation arrangements.

Frequently Asked Questions

The main purpose is to allow executives and directors to voluntarily defer the receipt of equity awards granted under specific company plans. This provides them with more flexibility in managing their compensation and potential tax liabilities.

The amendments to the Supplemental Savings Plan and the Voluntary Board of Directors Savings Plan are effective as of January 1, 2012.

The deferral option applies to equity awards granted under Biogen Idec's 2008 Omnibus Equity Plan and the 2006 Non-Employee Directors Equity Plan, as well as any future successor plans.

This filing primarily concerns the mechanics of how certain existing or future equity awards can be received by executives and directors, rather than announcing new grants or a fundamental shift in compensation philosophy. It's an enhancement to the existing compensation structure.